Education
About Us
Working with TipRanks
Follow Us
Barinthus Biotherapeutics (BRNS)
NASDAQ:BRNS
BRNS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.64 - $2.92
Previous CloseN/A
Volume10.26K
Average Volume (3M)2.57M
Market Cap
$55.67M
Enterprise Value-$49.40M
Total Cash (Recent Filing)$99.12M
Total Debt (Recent Filing)$11.92M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Nov 06, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding40,339,394
10 Day Avg. Volume88,417
30 Day Avg. Volume2,570,321
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.89
Enterprise Value/Revenue-8.52
Enterprise Value/Gross Profit-3.28
Enterprise Value/Ebitda0.84
Forecast
1Y Price Target
$3.00Price Target Upside106.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial StabilityCash runway into 2027 with $100.6M in cash and restricted cash, and management expects existing capital to fund operations into 2027.
Partnership OpportunitiesThe Phase I/II PCA001 trial was completed with signs of immunogenicity and no treatment-related serious adverse events, which will facilitate partnership discussions.
Research And DevelopmentVTP-300 data in chronic hepatitis B presented positive results from two Phase 2 trials, with some participants achieving functional cure and seroconversion.
Bears Say
Financial PerformanceNet loss was $19.6M, or ($0.49) per share, more than the estimated loss of $12.0M due to foreign exchange, asset depreciation and workforce reduction.
Impairment ExpensesFor 4Q24, net loss was $20.5M, or ($0.51) per share, more than the estimated loss of $11.5M due to $12.2M of goodwill impairment.
Regulatory And Clinical RisksRisks include failure of therapeutic candidates in clinical trials and failure to secure regulatory approval.
Barinthus Biotherapeutics News
BRNS FAQ
What was Barinthus Biotherapeutics’s price range in the past 12 months?
Barinthus Biotherapeutics lowest stock price was $0.64 and its highest was $2.92 in the past 12 months.
What is Barinthus Biotherapeutics’s market cap?
Barinthus Biotherapeutics’s market cap is $55.67M.
When is Barinthus Biotherapeutics’s upcoming earnings report date?
Barinthus Biotherapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 90 days.
How were Barinthus Biotherapeutics’s earnings last quarter?
Barinthus Biotherapeutics released its earnings results on Aug 07, 2025. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.33 by -$0.19.
Is Barinthus Biotherapeutics overvalued?
According to Wall Street analysts Barinthus Biotherapeutics’s price is currently Undervalued.
Does Barinthus Biotherapeutics pay dividends?
Barinthus Biotherapeutics does not currently pay dividends.
What is Barinthus Biotherapeutics’s EPS estimate?
Barinthus Biotherapeutics’s EPS estimate is -0.38.
How many shares outstanding does Barinthus Biotherapeutics have?
Barinthus Biotherapeutics has 40,339,394 shares outstanding.
What happened to Barinthus Biotherapeutics’s price movement after its last earnings report?
Barinthus Biotherapeutics reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.33. Following the earnings report the stock price went up 10.687%.
Which hedge fund is a major shareholder of Barinthus Biotherapeutics?
Currently, no hedge funds are holding shares in BRNS
Barinthus Biotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (106.90% Upside)
$3.00 (106.90% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.75%
12-Months-Change
Fundamentals
Return on Equity
-45.40%
Trailing 12-Months
Asset Growth
-28.82%
Trailing 12-Months
Company Description
Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
BRNS Stock 12 Month Forecast
Average Price Target
$3.00
▲(106.90% Upside)
Technical Analysis
Collplant Holdings
―
ALX Oncology Holdings
―
Aligos Therapeutics
―
CytoMed Therapeutics Limited
―
Boundless Bio Inc.
―
Ownership Overview
3.54%
Insiders
0.03% Mutual Funds
22.97% Other Institutional Investors
73.47% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---